erlotinib hydrochloride has been researched along with azd4547 in 4 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (azd4547) | Trials (azd4547) | Recent Studies (post-2010) (azd4547) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 117 | 6 | 116 |
| Protein | Taxonomy | erlotinib hydrochloride (IC50) | azd4547 (IC50) |
|---|---|---|---|
| Fibroblast growth factor receptor 1 | Homo sapiens (human) | 0.006 | |
| Fibroblast growth factor receptor 2 | Homo sapiens (human) | 0.0052 | |
| Fibroblast growth factor receptor 4 | Homo sapiens (human) | 0.3382 | |
| Fibroblast growth factor receptor 3 | Homo sapiens (human) | 0.0068 | |
| Vascular endothelial growth factor receptor 2 | Homo sapiens (human) | 0.0383 | |
| Fibroblast growth factor receptor 4 | Mus musculus (house mouse) | 0.4335 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baladandayuthapani, V; Bekele, BN; Dai, B; Jayachandran, G; Ji, L; Kawashima, H; Lara-Guerra, H; Majidi, M; Mehran, R; Meng, F; Roth, JA; Sakai, R; Wang, J; Wang, Y; Yan, S; Ying, J; Yoo, SY | 1 |
| Berndsen, RH; Ding, X; Dyson, PJ; Griffioen, AW; Ho, CM; Nowak-Sliwinska, P; van den Bergh, H; Weiss, A | 1 |
| Carnero, A; Cirauqui, C; Conde, E; Enguita, AB; Ferrer, I; Marrugal, Á; Molina-Pinelo, S; Ojeda-Márquez, L; Paz-Ares, L; Ponce-Aix, S; Quintanal-Villalonga, A; Suarez, R | 1 |
| Carnero, A; Enguita, AB; Ferrer, I; Marrugal, Á; Molina-Pinelo, S; Ojeda-Márquez, L; Paz-Ares, L; Ponce-Aix, S; Quintanal-Villalonga, A; Suarez, R; Yagüe, P | 1 |
4 other study(ies) available for erlotinib hydrochloride and azd4547
| Article | Year |
|---|---|
Exogenous Restoration of TUSC2 Expression Induces Responsiveness to Erlotinib in Wildtype Epidermal Growth Factor Receptor (EGFR) Lung Cancer Cells through Context Specific Pathways Resulting in Enhanced Therapeutic Efficacy.
Topics: Animals; Apoptosis; Benzamides; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Down-Regulation; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mice; Neoplasm Metastasis; Piperazines; Pyrazoles; Receptor, Fibroblast Growth Factor, Type 2; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Treatment Outcome; Tumor Stem Cell Assay; Tumor Suppressor Proteins | 2015 |
A streamlined search technology for identification of synergistic drug combinations.
Topics: Antineoplastic Agents; Axitinib; Benzamides; Cell Line, Tumor; Cell Survival; Dasatinib; Dose-Response Relationship, Drug; Drug Combinations; Drug Screening Assays, Antitumor; Drug Synergism; Epithelial Cells; Erlotinib Hydrochloride; Humans; Imidazoles; Indazoles; Kidney; Piperazines; Pyrazoles | 2015 |
FGFR1 Cooperates with EGFR in Lung Cancer Oncogenesis, and Their Combined Inhibition Shows Improved Efficacy.
Topics: Acrylamides; Aniline Compounds; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Carcinogenesis; Cell Line, Tumor; Drug Synergism; Enzyme Activation; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Receptor, Fibroblast Growth Factor, Type 1; Transfection; Xenograft Model Antitumor Assays | 2019 |
FGFR4 increases EGFR oncogenic signaling in lung adenocarcinoma, and their combined inhibition is highly effective.
Topics: Adenocarcinoma of Lung; Animals; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Cohort Studies; Drug Synergism; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Mice; Mice, Nude; Neoplasm Staging; Piperazines; Pyrazoles; Receptor, Fibroblast Growth Factor, Type 4; Respiratory Mucosa; Signal Transduction; Xenograft Model Antitumor Assays | 2019 |